Merck & Co.
American multinational pharmaceutical company
MRK NYSE
ISIN US58933Y1055 SEC CIK 310158 LEI 4YV9Y5M8S0BRK1RP0397
Follow Merck & Co.
Weekly email: filings, results
Revenue, last quarter
$18.1B
+4.7% vs same quarter last year
Net income
$5.1B
−12.4% vs same quarter last year
EPS, diluted
$2.04
−12.1% vs same quarter last year
Operating cash flow
$6.6B
−16.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $65B | $18.3B |
| FY24 | $64.2B | $17.1B |
| FY23 | $60.1B | $365M |
| FY22 | $59.3B | $14.5B |
| FY21 | $48.7B | $12.3B |
| FY20 | $41.5B | $7.1B |
| FY19 | $39.1B | $9.8B |
| FY18 | $42.3B | $6.2B |
| FY17 | $40.1B | $2.4B |
| FY16 | $39.8B | $3.9B |
| FY15 | $39.5B | $4.4B |
| FY14 | $42.2B | $11.9B |
| FY13 | $44B | $4.4B |
| FY12 | $47.3B | $6.2B |
| FY11 | $48B | $6.3B |
- Gross margin
- Net margin
Show the numbers
| Year | Gross margin | Net margin |
|---|---|---|
| FY25 | 74.8% | 28.1% |
| FY24 | 76.3% | 26.7% |
| FY23 | 73.2% | 0.6% |
| FY22 | 70.6% | 24.5% |
| FY21 | 72% | 25.3% |
| FY20 | 67.2% | 17% |
| FY19 | 69.3% | 25.2% |
| FY18 | 68.1% | 14.7% |
| FY17 | 67.8% | 6% |
| FY16 | 64.8% | 9.8% |
| FY15 | 62.2% | 11.2% |
| FY14 | 60.3% | 28.2% |
| FY13 | 61.5% | 10% |
| FY12 | 65.2% | 13% |
| FY11 | 64.9% | 13.1% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $12.4B |
| FY24 | $18.1B |
| FY23 | $9.1B |
| FY22 | $14.7B |
| FY21 | $8.7B |
| FY20 | $5.8B |
| FY19 | $10.1B |
| FY18 | $8.3B |
| FY17 | $4.6B |
| FY16 | $8.8B |
| FY15 | $11.3B |
| FY14 | $6.7B |
| FY13 | $10.1B |
| FY12 | $8.1B |
| FY11 | $10.7B |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $8.2B | $5.1B |
| FY24 | $7.8B | $1.3B |
| FY23 | $7.4B | $1.3B |
| FY22 | $7B | $0 |
| FY21 | $6.6B | $840M |
| FY20 | $6.2B | $1.3B |
| FY19 | $5.7B | $4.8B |
| FY18 | $5.2B | $9.1B |
| FY17 | $5.2B | $4B |
| FY16 | $5.1B | $3.4B |
| FY15 | $5.1B | $4.2B |
| FY14 | $5.2B | $7.7B |
| FY13 | $5.2B | $6.5B |
| FY12 | $5.1B | $2.6B |
| FY11 | $4.7B | $1.9B |
- Merck & Co.
- Healthcare median
Show the numbers
| Year | Merck & Co. | Healthcare median |
|---|---|---|
| FY25 | 28.1% | −30.6% |
| FY24 | 26.7% | −47% |
| FY23 | 0.6% | −58% |
| FY22 | 24.5% | −80.4% |
| FY21 | 25.3% | −71.9% |
| FY20 | 17% | −62.2% |
| FY19 | 25.2% | −46.3% |
| FY18 | 14.7% | −49.6% |
| FY17 | 6% | −45.9% |
| FY16 | 9.8% | −36% |
| FY15 | 11.2% | −38.4% |
| FY14 | 28.2% | −35.5% |
| FY13 | 10% | −37.1% |
| FY12 | 13% | −29.1% |
| FY11 | 13.1% | −27.9% |